A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate ...

VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with ...

Next-Generation Biopharmaceuticals Transforming the Global Therapeutic LandscapeThe Global Bio Pharmaceuticals Market is ...

The Parker Institute for Cancer Immunotherapy (PICI), today announced that research and expertise from across its network will be showcased at the 2025 Annual Meeting of the Society for Immunotherapy ...

Virginia Tech researchers have shown that memory loss in aging may be reversible. Using CRISPR tools, they corrected molecular disruptions in the hippocampus and amygdala, restoring memory in older ...

Memory problems may not be an unavoidable part of getting older. New findings from Virginia Tech reveal that age-related memory loss stems from ...

What if clinicians could place tiny electronic chips in the brain that electrically stimulate a precise target, through a ...

Cathie Wood's ARK Invest bought $17M in CRISPR and Beam gene-editing stocks while selling Teradyne, Roku, and SoFi shares on ...